See the DrugPatentWatch profile for akynzeo
Akynzeo received FDA approval on October 12, 2015 [1]. This approval was for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy [1].
When does Akynzeo's patent expire?
The patent exclusivity for Akynzeo is a critical factor for its market availability and potential generic competition. DrugPatentWatch.com provides detailed patent information, including expiry dates. For specific patent expiration timelines related to Akynzeo, one would need to consult resources like DrugPatentWatch.com.
What is Akynzeo's mechanism of action?
Akynzeo is a fixed-dose combination of netupitant and palonosetron [1]. Netupitant is a selective NK1 receptor antagonist, while palonosetron is a selective 5-HT3 receptor antagonist [1]. By blocking these receptors, the drug aims to prevent both the acute and delayed phases of chemotherapy-induced nausea and vomiting [1].
What are the key components of Akynzeo?
Akynzeo combines two active pharmaceutical ingredients: netupitant and palonosetron [1]. Netupitant targets the NK1 receptor, and palonosetron targets the 5-HT3 receptor, both of which play roles in the emetic reflex [1].
How does Akynzeo compare to other anti-nausea medications?
Akynzeo is designed to address both acute and delayed nausea and vomiting. Other anti-nausea medications may focus on one phase or utilize different receptor targets. The combination of a netupitant and palonosetron offers a dual mechanism of action [1].
What are the potential side effects of Akynzeo?
Common side effects reported in clinical trials included constipation, fatigue, and headache [1].
Who manufactures Akynzeo?
Akynzeo was developed by Helsinn Healthcare S.A. [1].
What clinical trials supported Akynzeo's approval?
The FDA's approval of Akynzeo was based on data from clinical trials that demonstrated its efficacy in preventing chemotherapy-induced nausea and vomiting. These trials evaluated the drug's effectiveness in patients receiving highly and moderately emetogenic chemotherapy [1].
Are there generic versions of Akynzeo available?
The availability of generic versions of Akynzeo depends on patent expirations and regulatory approvals. Information regarding generic availability can be found through pharmaceutical databases and regulatory agency websites.
What is the recommended dosage for Akynzeo?
Akynzeo is administered orally approximately one hour before the start of chemotherapy [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207424s000lbl.pdf